COMP <GO>
MASS vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
908 Devices Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: MASS 4
— TMO 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MASS
LAST: $12.85 (-0.15%) • MKT CAP: $531.1M
balance-sheet
5.54
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MASS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MASS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.30% | -44.30 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.64% | 2.40% | -7.04 | TMO | /fcf-yield <GO> |
| Operating Margin | -60.00% | 17.40% | -77.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 34.70% | 15.10% | +19.60 | MASS | /net-margins <GO> |
| Revenue Growth (YoY) | 17.70% | 3.90% | +13.80 | MASS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.54 | 4.50 | +1.04 | MASS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.7 | 62.9 | -4.20 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.9x | 36.3x | -13.40 | MASS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $531.1M | $262.22B | -$261.69B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MASS REV | TMO REV | MASS GROSS % | TMO GROSS % | MASS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $56.2M | $44.56B | 50.6% | — | -$24.6M | $6.29B |
| FY 2024 | $47.7M | $42.88B | 51.3% | — | -$30.8M | $7.27B |
| FY 2023 | $50.2M | $42.86B | — | — | -$25.1M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MASS // BETA —
TMO // BETA 0.94